BUILDING BLOCKS OF PATIENT CARE JOURNAL SCAN: A REVIEW OF 30 RECENT PAPERS OF IMMEDIATE CLINICAL SIGNIFICANCE, HARVESTED FROM MAJOR INTERNATIONAL JOURNALS Editorial: Celebrating Research Excellence and Clinical Innovation at Kauvery Hospitals INSTRUCTIONS TO AUTHORS ROTATHON-SERIES OF SUCCESSFUL ROTA CASES LAST 2 MONTHS: AN AUDIT OUTCOMES OF AKI AUDIT IN KAUVERY ETIOLOGY, CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ACUTE PANCREATITIS IN KAUVERY CANTONMENT HOSPITAL (KCN), TRICHY USE OF BLOOD PRODUCTS AND STEROIDS IN THE MANAGEMENT OF DENGUE AT KAUVERY TRICHY HOSPITALS: A CLINICAL AUDIT A CLINICAL AUDIT: ON THE MANAGEMENT OF ECTOPIC PREGNANCY DIABETIC KETOACIDOSIS WITH HIGH ANION GAP METABOLIC ACIDOSIS HYPOKALEMIC PARALYSIS FROM DISTAL RENAL TUBULAR ACIDOSIS (TYPE-1) DELAYED PRESENTATION OF INTERMEDIATE SYNDROME IN A PATIENT WITH ORGANOPHOSPHORUS POISONING: A CASE REPORT SCAPULA FRACTURES: DO WE NEED TO FIX THEM
Consider a Blue Horizon test if you need a more detailed "snapshot" to guide your next steps
Our administrative staff will help you verify insurance coverage and outline the costs involved, so you can make an informed decision about your care
Our physician injectors use specific types of filler under the eyes that swell much less than other options, and this allows us to be very precise in the amount placed, to ensure we do not over-fill the area
NOT for human or animal consumption
For instance in the SCALE trials, non-completing patients typically discontinued liraglutide 3.0 mg due to tolerability issues, whereas non-completing patients typically discontinued placebo due to lack of effect, and there are no strong arguments to suggest that the patients who discontinued placebo would also have been the patients who would experience tolerability issues had they been randomized to liraglutide 3.0 mg instead
